Rezzayo (Rezafungin)

REZZAYO is an echinocandin antifungal indicated for patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO.

Limitations of Use

REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.

Dosage And Administration  

Administer the recommended dosage of REZZAYO once weekly by intravenous (IV) infusion, with an initial 400 mg loading dose, followed by a 200 mg dose once weekly thereafter. The safety of REZZAYO has not been established beyond 4 weekly doses.

• See full prescribing information for reconstitution, dilution, and administration instructions.

If you are considering the import of Rezzayo to India, please be aware that Rezzayo can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

• The order for Elahere will be confirmed upon the receipt of the following documents:
• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Rezzayo in India: 

Rezzayo (Rezafungin) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Rezzayo (Rezafungin) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Rezzayo (Rezafungin)

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Rezzayo (Rezafungin) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.

Is rezafungin approved by the FDA?

The FDA has approved rezafungin for injection (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) for the treatment of candidemia and invasive candidiasis in individuals with limited or no alternative treatment options.

What is the brand name for rezafungin?

Rezafungin (trade name Rezzayo) is an antifungal drug of the echinocandin class. Rezafungin was approved by the Food and Drug Administration in March 2023 for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.

What is the new antifungal drug in 2023?

On March 22, 2023, the US Food and Drug Administration (FDA) approved Cidara’s New Drug Application (NDA) for rezafungin injection for the treatment of candidaemia and invasive candidiasis (C/IC) in patients 18 years of age or older who have limited or no alternative treatment options

What is the new antifungal FDA approved?

The U.S. Food and Drug Administration (FDA) has approved rezafungin for injection, (REZZAYO), a treatment for patients with candidemia and invasive candidiasis.